

Bioconjugation and more in the field of Antibody Drug Conjugate (Dr Alain Wagner)

Continuous success of antibody drug conjugates put on the market demonstrates the considerable therapeutic potential of this approach. However, it also reveals huge opportunity for improvement and innovation. Many of these rely on the understanding and control tight of chemical bond forming and bond breaking processes in defined biological environment.

In this context, we have carried studies with the aim to reach better ADC by to improving bioconjugation efficacy, controlling payload liberation and combining payloads with complementary mode of actions. Examples of our strategies, findings and current thought will be presented.